Cancer Vaccines Market to Reach USD 17.42 Billion by 2030, Fueled by mRNA Innovation and Preventive Programs

Mordor Intelligence has published a new report on the Cancer Vaccines Market, offering a comprehensive analysis of trends, growth drivers, and future projections.

The cancer vaccines market is projected to grow from USD 10.67 billion in 2025 to USD 17.42 billion by 2030, at a compound annual growth rate (CAGR) of 10.30% during the forecast period. This growth reflects increasing adoption of both preventive and therapeutic vaccine platforms, supported by advancements in personalized mRNA and neoantigen technologies, as well as government-led HPV immunization programs. North America leads in market size, while Asia‐Pacific shows rapid expansion driven by cost-effective production and rising cancer incidence.

Report Overview: https://www.mordorintelligence.com/industry-reports/cancer-vaccines-market?utm_source=openpr

Key Trends

Shift toward Personalized mRNA and Neoantigen Vaccines
The development of individualized cancer vaccines-tailored to each patient's tumor mutations-is accelerating globally. Predictive AI models are refining epitope selection, and modular manufacturing facilities shorten production timelines.

Preventive Vaccines Dominate Early Adoption
HPV-based cancer prevention vaccines continue to account for the majority of current market revenue, supported by expanding immunization programs and regulatory approvals. Interest in therapeutic vaccine candidates is growing rapidly, fueled by promising clinical data.

mRNA Platforms Lead Growth in Asia-Pacific
While recombinant cancer vaccine types remain established, mRNA and neoantigen platforms are growing fastest in the Asia‐Pacific region. Regional projects in China, India, and South Korea support local vaccine development and distribution capacity at more affordable costs.

Combination Therapies Gain Ground
Cancer vaccines are increasingly studied in combination with checkpoint inhibitors, adoptive cell therapies, and adjuvant regimens to improve durability and efficacy-especially in melanoma, cervical, and pancreatic cancer trials.

Regulatory Alignment Supports Cross‐Border Trials
FDA breakthrough therapy designations, EMA PRIME approvals, and global harmonization of trial standards have reduced barriers to multinational studies and fast-track access to novel cancer vaccine therapies

Market Segmentation

By Technology

Recombinant Vaccines

Viral Vector & DNA Vaccines

mRNA/Neoantigen Personalised Vaccines

Whole-cell & Dendritic Cell Vaccines

Other Technologies

By Treatment Method

Preventive Vaccines

Therapeutic Vaccines

By Cancer Type

Cervical Cancer (HPV)

Prostate Cancer

Melanoma

Other Cancers

By Delivery Route

Intramuscular

Intradermal / Sub-cutaneous

Intravenous

By Region:

North America

Europe

Asia‐Pacific

South America

Middle East & Africa

Explore Our Full Library of Healthcare Industry Research Reports

https://www.mordorintelligence.com/market-analysis/healthcare?utm_source=openpr

Key Players

Major companies active in the global cancer vaccines market include:

OSE Immunotherapeutics

GlaxoSmithKline PLC

F Hoffmann-La Roche AG (Genentech)

Moderna Inc.

Merck & Co. Inc.

For more information, visit: https://www.mordorintelligence.com/industry-reports/cancer-vaccines-market/companies?utm_source=openpr

Conclusion

The global cancer vaccines market is on track to expand from USD 10.67 billion in 2025 to USD 17.42 billion by 2030, exhibiting a 10.30% CAGR. Preventive vaccines, especially HPV formulations, continue to dominate current revenues, while therapeutic and personalized vaccine segments are attracting major investment and clinical momentum.

North America remains the largest market, thanks to established health infrastructure and early adoption. Asia‐Pacific, with regional vaccine development capacity, is the fastest-growing region in terms of revenue. Technological shifts toward mRNA and neoantigen platforms, paired with AI-guided design and streamlined regulatory pathways, are accelerating personalized vaccine development.

Industry Related Reports

Asia-Pacific Cancer Vaccines Market: The Asia-Pacific Cancer Vaccines Market is Segmented by Technology (Recombinant Vaccines, and More), Treatment Method (Preventive Vaccines and Therapeutic Vaccines), Cancer Type (Cervical Cancer (HPV), Melanoma and More), Delivery Route (Intramuscular, Intravenous, and More), and Geography (China, Japan, India, and More).
Get More Insights: https://www.mordorintelligence.com/industry-reports/asia-pacific-cancer-vaccines-market?utm_source=openpr

Therapeutic Vaccine Market: The Therapeutic Vaccine Market is Segmented by Products (Autoimmune Disease Vaccines, Cancer Vaccines, and More), Technology (Allogeneic Vaccines and Autologous Vaccines), Age Group (Adults and More), Distribution Channel (Public and Private) and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, South America).
Get More Insights: https://www.mordorintelligence.com/industry-reports/global-therapeutic-vaccines-market-industry?utm_source=openpr

Oncology Based In-Vivo CRO Market: Oncology Based In-Vivo Contract Research Organization (CRO) Market is segmented by Indication (Blood Cancer, Solid Tumors, and Other Indication), Model (Syngeneic, Xenograft, Patient Derived Xenograft (PDX)), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America).

Get More Insights: https://www.mordorintelligence.com/industry-reports/oncology-based-in-vivo-cro-market?utm_source=openpr

About Mordor Intelligence:

Mordor Intelligence is a trusted partner for businesses seeking comprehensive and actionable market intelligence. Our global reach, expert team, and tailored solutions empower organizations and individuals to make informed decisions, navigate complex markets, and achieve their strategic goals.

With a team of over 550 domain experts and on-ground specialists spanning 150+ countries, Mordor Intelligence possesses a unique understanding of the global business landscape. This expertise translates into comprehensive syndicated and custom research reports covering a wide spectrum of industries, including aerospace & defense, agriculture, animal nutrition and wellness, automation, automotive, chemicals & materials, consumer goods & services, electronics, energy & power, financial services, food & beverages, healthcare, hospitality & tourism, information & communications technology, investment opportunities, and logistics.

For any inquiries or to access the full report, please contact:

media@mordorintelligence.com
https://www.mordorintelligence.com/

Mordor Intelligence, 11th Floor, Rajapushpa Summit, Nanakramguda Rd, Financial District, Gachibowli, Hyderabad, Telangana - 500032, India

Mordor Intelligence is a trusted partner for businesses seeking comprehensive and actionable market intelligence. Our global reach, expert team, and tailored solutions empower organizations and individuals to make informed decisions, navigate complex markets, and achieve their strategic goals.

With a team of over 550 domain experts and on-ground specialists spanning 150+ countries, Mordor Intelligence possesses a unique understanding of the global business landscape. This expertise translates into comprehensive syndicated and custom research reports covering a wide spectrum of industries, including aerospace & defense, agriculture, animal nutrition and wellness, automation, automotive, chemicals & materials, consumer goods & services, electronics, energy & power, financial services, food & beverages, healthcare, hospitality & tourism, information & communications technology, investment opportunities, and logistics.

For any inquiries or to access the full report, please contact:

media@mordorintelligence.com
https://www.mordorintelligence.com/

This release was published on openPR.